Figure S8 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

Q: What type of study is this?

This is a Quantitative Study study.

Kunling Chen; Huolun Feng; Yujie Zhang; Jingyuan Pei; Yuyan Xu; Xiangxu Wei; Zhuohao Chen; Zhoubin Feng; Lei Cai; Yong Li; Liang Zhao; Mingxin Pan

doi:10.1158/0008-5472.30254923

October 1, 2025

Figure S8 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

View at Publisher

Ask AI

Bookmark

Share

Key Points

Normalization of tumor vasculature is achieved through CCL16, enhancing immune response.
Therapeutic effects of DPP4 inhibitors were noted in the study of hepatocellular carcinoma.
Macrophage ICAM-1 receptor involvement signifies a crucial pathway in tumor metabolism.
Findings may lead to more effective immunotherapy protocols for liver cancer patients.

Implication

Findings reveal CCL16 normalizes tumor vasculature and enhances immune therapy efficacy in hepatocellular carcinoma, suggesting new treatment strategies.

Abstract

CCL16 degradation in the HCC microenvironment and therapeutic potential of DPP4 inhibitors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21b04 https://doi.org/10.1158/0008-5472.30254923

View at Publisher

Ask AI

Bookmark

Share

Figure S8 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S8 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading